Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property
The company is now prioritizing internal discovery endeavors to tackle the major current limitations of CAR T-cell therapies
As of December 31, 2022, the Company ended the year with an unaudited treasury position of €12.4 million ($13.3 million)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.